Učitavanje...
New questions regarding bioequivalence of levothyroxine preparations: A Clinician's response
A recent decision by the Food and Drug Administration (FDA) to declare various brands of levothyroxine bioequivalent has provoked objections from several physicians' organizations. These organization assert that the method of testing bioequivalence is flawed, and that indiscriminate switching a...
Spremljeno u:
| Glavni autor: | |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Springer-Verlag
2005
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2751497/ https://ncbi.nlm.nih.gov/pubmed/16146330 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1208/aapsj070107 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|